姓名：韩涛
职称：教授、主任医师
一、教育经历
1995.9–1999.7,首都医科大学, 内科学, 博士
1991.9–1994.7, 天津医科大学, 内科学, 硕士
1984.9–1989.7, 华中科技大学同济医学院, 临床医学, 学士
2004.9- 2005.9, 美国Mayo Clinic, SRF
二、工作经历
1989.8-1994.7天津市第三中心医院消化（肝病）科
医师
1994.7-1999.7天津市第三中心医院消化（肝病）科
主治医师
1999.7-2004.11 天津市第三中心医院消化（肝病）科
副主任医师
2004.11-至今天津市第三中心医院消化（肝病）科
主任医师
2005.12-2013.9 天津市第三中心医院消化（肝病）科
科主任
2006.11-至今天津市第三中心医院副院长
三、主要研究方向（包括近年主要承担课题项目）
肝脏疾病的临床与基础研究
主要承担课题项目：
1. “艾滋病和病毒性肝炎等重大传染病防治”科技重大专项，2017ZX，重症乙型肝炎（肝衰竭）临床治疗新技术研究及新方案推广（子课题），2017/01-2020/12，主持
2.“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项，2012ZX**-011，乙肝肝衰竭新型预警及干预策略的研究（子课题），2015/01-2019/12，主持
3. 国家自然科学基金面上项目，**，Tβ4通过下调lncRNA-AIRN抑制肝细胞焦亡缓解急性肝损伤的机制研究，2019/01-2022/12，主持
4. 国家自然科学基金面上项目，**，lncRNA-LFAR1在肝纤维化发病过程中的作用及机制研究，2017/01-2020/12，第二完成人
四、学术兼职
目前兼任中华医学会肝病学分会常委、中华医学会重型肝病与人工肝学组组长、全国疑难及重症肝病攻关协作组副组长、天津市肝病学分会主任委员等，曾任天津市生天津物医学工程学会理事、常务理事；中国抗癌协会纳米肿瘤分会委员、天津市中西医结合肝病分会副主任委员、中国医师协会消化分会全国委员、中国医师协会感染病分会常委等。为国内外10余种专业期刊编委。
五、近五年发表的主要学术论文
1. Wang F, Liu H, Wang F, Xu R, Wang P, Tang F, Zhang X, Zhu Z, Lv H, Han T. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep. 2018, 17(4): 5213-5221.
2. Jiang Y, Han T, Zhang ZG, Zhang Y, Qi FX. Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis. Rev Esp Enferm Dig. 2018, 110(1): 19-24.
3. Zhang K, Han XH, Zhang Z, Zheng LN, Hu ZM, Yao QB, Cui HM, Shu GM, Si MJ, Li C, Sh ZM, Chen T, Han YW, Chang YN, Yao Z, Han T&Hong W. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβand Notch pathways. Nature Communications. 2017, 8(1): 144.
4. Ye Q, Yin W, Zhang L, Xiao H, Qi Y, Liu S, Qian B, Wang F, Han T. The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis. PloS One, 2017, 12(4): e**.
5. Cai JJ, Zhang M, Han T, Jiang HQ. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017, 96(37): e8057.
6. Jiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med. 2017, 3(3): 165-168.
7. Zhang K, Chang YN, Shi ZM, Han XH, Han YW, Yao QB, Hu ZM, Cui HM, Zheng LN, Han T, Hong W.ω-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP/TAZ degradation. Scientific Reports. 2016, 6: 30029.
8. Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PloS One. 2016, 11(9): e**.
9. Liang J, Cai WJ, Han T, Jing L, Ma Z, Gao YT. The expression of thymosin beta4 in chronic hepatitis B combined nonalcoholic fatty liver disease. Medicine (Baltimore). 2016, 95(52): e5763.
10. Jiang Y, Zhang ZG, Qi FX, Zhang Y, Han Y. Comparison of maintenance effect of probiotifcs and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. Chronic Diseases and Translational Medicine. 2016,2(1): 34-41.
11. Cai JJ, Han T, Nie CY, Jia XB, Liu Y, Zhu ZY, Gao YT. Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure. Clin Res Hepatol Gastroentero. 2016, 40(1): 41-50.
12. Yin WL, Ye Q, Wang FM, Liang J, Xu BG, Zhang X, Zhang Q, Liu Y, Li G, Han T. ART score and hepatocellular carcinoma: An appraisal of its applicability. Clin Res Hepatol Gastroenterol, 2016, 40(6):705-714.
13. Zhang Q, Han T, Li Y, et al. Predictors of progression into acute-on-chronic liver failure from acute deterioration of preexisting chronic liver disease. Hepatol Res. 2016, 46(4): 320-328.
14. Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, Liu Y. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One. 2015, 10(3): e**.
15. Liang J, Han T, Gao YT, Jing L, Ma Z. The expression of serum M30 and M65in chronic hepatitis B patients with non-alcoholic fatty liver disease.European Review for Medical and Pharmacological Sciences. 2015, 19 (21): 4123-4129.
16. Zhang Q, Han T, Nie CY, et al. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. J Med Virol. 2015, 87(6): 1013-1021.
17. Han LY, Han T, Nie CY, et al. Elevated mean platelet volume is associated with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. Clin Res Hepatol Gastroenterol. 2015, 39(3): 331-339.
18. NieXH, Han T, Zhang L, Li Y, Liu H, Xiao SX, Li Y, Kang H, Liu SY. Comparison of effects of the pretreatment and treatment with RhIL-11 on acute liver failure induced by D-galactosamine. European Review for Medical and Pharmacological Science. 2014, 18(8): 1142-1150.
19. Liu Y, Han T, Zhu ZY, Li Y. Thymosin beta4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient. Clin Res Hepatol Gastroenterol. 2014, 38(3): 310-317.
20. Nie CY, Han T, Zhang L, Li Y, Liu H, Xiao SX, Li Y, Kang H, Liu SY. Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. J Viral Hepatitis. 2014, 21(1): 53-63.
六、荣誉和奖励
曾获天津市首批有突出贡献专家、天津市科技奖6项。
七、联系方式
1.通讯地址：天津市河东区津塘路83号
2.电话：
3. E-mail：hantaomd@126.com